Business

Mass. Movers

Celldex studying kidney disease therapy

Celldex has started a pilot study on a new treatment.

istockphoto.com

Celldex has started a pilot study on a new treatment.

Shares of Celldex Therapeutics continued to rise on Friday, four days after the company said it has begun a pilot study of a treatment for a rare kidney disease called dense deposit disease. Celldex said the first patient was dosed in the study of the disease, which ultimately results in kidney failure for most patients. Celldex has its operations office in Needham and also operates a manufacturing plant in Fall River, among other facilities in the Northeast.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
You're reading  1 of 5 free articles.
Get UNLIMITED access for only 99¢ per week Subscribe Now >
You're reading1 of 5 free articles.Keep scrolling to see more articles recomended for you Subscribe now
We hope you've enjoyed your 5 free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com